NCCN Task Force Report: Oral chemotherapy

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 6, Issue SUPPL. 3, 2008, Pages

  Weingart, Saul N ^a   Brown, Elizabeth ^b   Bach, Peter B ^c   Eng, Kirby ^d   Johnson, Shirley A ^e   Kuzel, Timothy M ^f   Langbaum, Terry S ^g   Leedy, R Donald ^h   Muller, Raymond J ^c   Newcomer, Lee N ⁱ   O'Brien, Susan ^j   Reinke, Denise ^k   Rubino, Mark ^l   Saltz, Leonard ^c   Walters, Ronald S ^j  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b National Comprehensive Cancer Network

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d CVS Caremark   (United States)

^e BARNES JEWISH HOSPITAL   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

^g JOHNS HOPKINS UNIVERSITY   (United States)

^h FOX CHASE CANCER CENTER   (United States)

ⁱ UnitedHealthcare ^*

^j UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^k UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^l AETNA   (United States)

more..

Author keywords

Cancer care; Chemotherapy administration; Coverage and reimbursement; NCCN Task Force Report; Oral chemotherapy; Parenteral chemotherapy; Patient adherence

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CETUXIMAB; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; ETANERCEPT; FLUOROURACIL; GEFITINIB; IMATINIB; INFLIXIMAB; LAPATINIB; LENALIDOMIDE; MERCAPTOPURINE; METHOTREXATE; NILOTINIB; PANITUMUMAB; PROTEIN TYROSINE KINASE INHIBITOR; SEROTONIN ANTAGONIST; SORAFENIB; SUNITINIB; TOPOTECAN; VORINOSTAT;

ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CAREGIVER; CHRONIC MYELOID LEUKEMIA; CONTINUOUS INFUSION; COST BENEFIT ANALYSIS; DIARRHEA; DRUG COST; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; ERYTHEMA; FEVER; FOOT PAIN; HEALTH CARE FINANCING; HOSPITAL PHARMACY; HUMAN; MOUTH PAIN; MULTIPLE MYELOMA; NURSE; PATIENT CARE; PATIENT COMPLIANCE; PATIENT COUNSELING; PATIENT EDUCATION; PATIENT SELECTION; PHARMACIST; RASH; SELF MONITORING; SWELLING; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VOMITING; NEOPLASMS; ORAL DRUG ADMINISTRATION; UNITED STATES;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; PATIENT COMPLIANCE; UNITED STATES;

EID: 41849112354     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Curtiss FR. Pharmacy benefit spending on oral chemotherapy drugs. J Managed Care Pharm 2006;12:57-77.
2. Schellens JHM. Challenges of oral chemotherapy. Clin Adv Hematol Oncol 2005;3:99-100.
3. Bowman J, Rousseau A, Silk D, Harrison D. Access to cancer drugs in Medicare Part D. Formulary placement and beneficiary cost sharing in 2006. Health Aff 2006;25:1240.
4. Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997;15:110-115.
5. Taylor JA, Winter L, Geyer LJ, Hawkins DS. Oral outpatient chemotherapy medication errors in children with acute lymphoblastic leukemia. Cancer 2006;107:1400-1406.
6. Viele CS. Managing oral chemotherapy: The health practitioner's role. Am J Health Syst Pharm 2007;64(Suppl 5):S25-32.
7. Partridge AH, Avorn J, Wong PS, Winer EP. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst 2002;94:652-661.
8. Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002;288:455-461.
9. Tsang J, Rudychev I, Pescatore SL. Prescription compliance and persistency in chronic myelogenous leukemia and gastrointestinal stromal tumor patients on imatinib [abstract]. J Clin Oncol 2006;24(Suppl 1):330s. Abstract 6119.
10. Osterberg L, Blaschke T. Adherence to medication. N Eng J Med 2005;353:487-497.
11. Weingart SN, Flug J, Brouillard D, et al. Oral chemotherapy safety practices at US cancer centres: questionnaire survey. BMJ 2007;334:407.
12. Basch B, Artz D, Dulko D, et al. Patient online self-reporting of toxicity symptoms during chemotherapy. J Clin Oncol 2005;23:3552-3561.
13. Basch E, Iasonos A, Barz A, et al. Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy. J Clin Oncol 2007;25:5374-5380.
14. Jacobson M, O'Malley AJ, Earle CC, et al. Does reimbursement influence chemotherapy treatment for cancer patients? Health Aff (Millwood) 2006;25:437-443.
15. Schneeweiss S, Patrick AR, Maclure M, et al. Adherence to statin therapy under drug cost sharing in patients with and without acute myocardial infarction: a population-based natural experiment. Circulation 2007;115:2128-2135.
16. Mannheim BS, Granahan P, Dow KJ. Follow-on biologics: ensuring continued innovation in the biotechnology industry. Health Affairs 2006;25:394-404.
17. Fendrick AM, Chernew ME. Value-based insurance design; a "clinically sensitive" approach to preserve quality and contain costs. Am J Manag Care 2006;12:18-20.
18. Denny CC, Emmanuel EJ, Pearson SD. Why well-insured patients should demand value-based insurance benefits. JAMA 2007;297:2515-2518.